Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BioCorRx (BICX) EBITDA Margin (2016 - 2025)

BioCorRx's EBITDA Margin history spans 15 years, with the latest figure at 306.05% for Q3 2025.

  • For Q3 2025, EBITDA Margin changed N/A year-over-year to 306.05%; the TTM value through Sep 2025 reached 569.42%, up 1745411.0%, while the annual FY2024 figure was 66412.77%, 6219320.0% down from the prior year.
  • EBITDA Margin for Q3 2025 was 306.05% at BioCorRx, up from 790.96% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 306.05% in Q3 2025 and bottomed at 33694.26% in Q2 2024.
  • The 5-year median for EBITDA Margin is 5449.39% (2022), against an average of 8788.56%.
  • The largest annual shift saw EBITDA Margin tumbled -2890445bps in 2024 before it skyrocketed 3290331bps in 2025.
  • A 5-year view of EBITDA Margin shows it stood at 9742.67% in 2021, then surged by 85bps to 1422.86% in 2022, then tumbled by -203bps to 4310.34% in 2023, then tumbled by -682bps to 33694.26% in 2024, then surged by 99bps to 306.05% in 2025.
  • Per Business Quant, the three most recent readings for BICX's EBITDA Margin are 306.05% (Q3 2025), 790.96% (Q2 2025), and 692.5% (Q1 2025).